Press releaseBusiness Wire
Rocket Pharmaceuticals
RCKT · NASDAQ
$2.34+$0.10 (+4.46%)TodayMarket closed ·
Prev close $2.24
Latest news
- Press releaseBusiness Wire
Rocket Pharmaceuticals Highlights FDA-Aligned Pivotal Phase 2 Trial and Updated Clinical Findings for RP-A501 Following Danon Disease Investor Webinar
- Press releaseBusiness Wire
Rocket Pharmaceuticals Secures Strategic Credit Facility for Up to $150 Million from Hercules Capital
- Press releaseBusiness Wire
Rocket Pharmaceuticals Announces FDA Alignment on Path to Complete Pivotal Phase 2 Trial of RP-A501 in Danon Disease
- Press releaseBusiness Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
Rocket Pharmaceuticals Reports Second Quarter 2026 Financial Results and Highlights Recent Progress
- NewsVandana Singh
Rocket Pharmaceuticals Touts Positive Early Safety Data from Revised Genetic Therapy Trial
- News
Rocket Pharma Announces Clinical Safety Update Regarding Initial Three Patients Treated Under Modified Protocol For Global, Pivotal Phase 2 Trial Of RP-A501 In Danon Disease
- Press releaseBusiness Wire
Rocket Pharmaceuticals Announces Positive Clinical Safety Update from Initial Three Patients Treated with RP-A501 Under Modified Phase 2 Protocol for Danon Disease
- Press releaseBusiness Wire
Rocket Pharmaceuticals Announces Closing of Sale of Rare Pediatric Disease Priority Review Voucher for $180 Million
- Press releaseBusiness Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
Rocket Pharmaceuticals Reports First Quarter 2026 Financial Results and Highlights Recent Progress
- Press releaseBusiness Wire
Rocket Pharmaceuticals Announces $180 Million Sale of Priority Review Voucher
- NewsVandana Singh
Why Is Rocket Pharma Stock Soaring Friday?
- News
12 Health Care Stocks Moving In Friday's Pre-Market Session
- Press releaseBusiness Wire
Rocket Pharmaceuticals Announces FDA Approval of KRESLADI™ for Pediatric Patients with Severe Leukocyte Adhesion Deficiency-I (LAD-I)
- Press releaseBusiness Wire
Rocket Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Highlights Recent Progress
- Press releaseBusiness Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
- Press releaseBusiness Wire
Rocket Pharmaceuticals to Participate in the 44th Annual J.P. Morgan Healthcare Conference
- Press releasePRNewswire
Beyond Traditional Drugs: Novel Platforms Targeting Hard-to-Treat Conditions
- Press releaseBusiness Wire
Rocket Pharmaceuticals to Participate in the 8th Annual Evercore Healthcare Conference
- NewsAvi Kapoor
Helmerich and Payne, Invivyd, Home Depot And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
- Press releaseBusiness Wire
Rocket Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Progress
- NewsVandana Singh
FDA's Rigid Approach Adds Uncertainty To uniQure's Accelerated Pathway For Huntington's Gene Therapy
- Press releaseGlobe Newswire
ROCKET ALERT: Bragar Eagel & Squire, P.C. is Investigating Rocket Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
- NewsVandana Singh
FDA Acceptance Of Rocket Pharmaceuticals' Lead Gene Therapy Application Reestablishes Momentum For Stock
- NewsAvi Kapoor
Domino's Pizza Posts Upbeat Results, Joins Astria Therapeutics, Albertsons Companies, Polaris And Other Big Stocks Moving Higher On Tuesday
- Press releaseBusiness Wire
Rocket Pharmaceuticals Announces FDA Acceptance of BLA Resubmission of KRESLADI™ for the Treatment of Severe Leukocyte Adhesion Deficiency-I (LAD-I)
- Press releaseBusiness Wire
Rocket Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Press releasePRNewswire
Kuehn Law Encourages Investors of Rocket Pharmaceuticals, Inc. to Contact Law Firm
- NewsVandana Singh
FDA Outlines Process To Speed Up Rare Disease Therapy Approvals
- Press releaseBusiness Wire
Rocket Pharmaceuticals to Participate in Upcoming Investor Conferences
- NewsAvi Kapoor
Coty, Bilibili, Canadian Solar And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
- NewsAvi Kapoor
Why Nordson Shares Are Trading Higher By Over 5%; Here Are 20 Stocks Moving Premarket
- NewsAvi Kapoor
TJX Posts Better-Than-Expected Earnings, Joins Rocket Pharmaceuticals, Guess? And Other Big Stocks Moving Higher On Wednesday
- News
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
- NewsAvi Kapoor
Why Rocket Pharmaceuticals Shares Are Trading Higher By Over 15%; Here Are 20 Stocks Moving Premarket
- NewsVandana Singh
What's Going On With Sarepta, Capricor And Other Gene Therapy Stocks On Wednesday?
- Press releaseBusiness Wire
Rocket Pharmaceuticals Announces Strategic Corporate Reorganization and Pipeline Prioritization of Cardiovascular Programs
Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.